Manchester, UK – 25 October 2018 - SkinBioTherapeutics plc (AIM: SBTX – “SkinBioTherapeutics” or the “Company”) a life sciences company focused on skin health, has announced its full year audited results for the year to 30 June 2018.
Cath O’Neill, CEO of SkinBioTherapeutics, said:
“This year, our focus has been on preparing the SkinBiotix® technology for its first human study and longer-term preparations for commercialisation. On both fronts, we have made good progress.
“Firstly, we have demonstrated that our lysate can be freeze dried and scaled-up to industrial levels. On the commercial front, we have an ongoing dialogue, including an MTA, with a range of major FMCG and cosmetic companies who are taking a close interest in our technology and progress.
“Post year end, we initiated the cosmetic human studies which was a major milestone for the Company. On the basis that the results are positive, the validation will strengthen our position as a science-led business and enable further commercial discussions.”
The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 and has been arranged for release by Doug Quinn, CFO of the Company. Upon the publication of this announcement, this inside information is now considered to be in the public domain.
For the full announcement, visit www.skinbiotherapeutics.com.
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin health. The Company’s proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O’Neill and Professor Andrew McBain.
SkinBioTherapeutics’ platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models. Proof of principle studies have shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas.
SkinBioTherapeutics received seed funding from the Tech Transfer office of the University of Manchester for the discovery of SkinBiotix®. The platform was subsequently spun out of the University of Manchester in March 2016 and was funded by OptiBiotix (AIM: OPTI).
The Company joined AIM in April 2017 concurrent with raising £4.5 million from a placing of new ordinary shares.
The Company is based in Manchester, UK. For more information, visit www.skinbiotherapeutics.com.
Issued for and on behalf of SkinBioTherapeutics plc by Instinctif Partners.
For more information please contact: email@example.com
Melanie Toyne-SewellManaging Partner